Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.

• Phase: Phase 2

Details

• Lead Sponsor: Vertex Pharmaceuticals Incorporated

Criteria

Inclusion Criteria:

• Diagnosed with chronic plaque psoriasis for at least 6 months

• Prior systemic therapy

Exclusion Criteria:

• Current or prior history of illness precluding use of immunomodulatory therapy.